TELA Bio, Inc. (NASDAQ: TELA ) reported mixed results for the fourth quarter on Tuesday .
The company posted quarterly losses of 17 cents per share which beat the analyst consensus estimate of losses of 18 cents per share. The company reported quarterly sales of $20.869 million which missed the analyst consensus estimate of $21.047 million.
TELA Bio said it sees first-quarter sales of $18.500 million versus market estimates of $21.277 million.
TELA Bio shares dipped 9.4% to close at $0.6901 on Wednesday.
These analysts made changes to their price targets on TELA Bio following earnings announcement.
Canaccord Genuity analyst Caitlin Roberts maintained TELA Bio with a Buy and lowered the price target from $4 to $2. Lake Street analyst Frank Takkinen maintained TELA Bio with a Buy and lowered the price target from $3 to $2. Piper Sandler analyst Matt O’Brien maintained the stock with a Neutral and lowered the price target from $1.25 to $1.Considering buying TELA stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Earnings News Price Target Markets Analyst Ratings Trading Ideas PT Changes